who prescribes glp 1 Insights from Specialty Physicians on GLP-1RA Medications Off-Label Use Get access to GLP-1 medication—prescribed

Participants with Class 1 obesity (BMI 30-35) averaged 10.2% weight loss at 12 weeks with the 12mg dose

Shorter-acting agents like liraglutide and exenatide may require a shorter washout, often around 4 weeks, depending on the clinical situation

Age 50+ (Especially Women) NAION is most common in people over 50, and women ages 50-64 are the highest users of GLP-1 medications (20-22%)

Back to Journals Vascular Health and Risk Management Volume 12 SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives Authors Gurgle H, White K, McAdam-Marx C Received 14 November 2015 Accepted for publication 11 March 2016 Published 4 June 2016 Volume 2016:12 Pages 239249 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 5 Editor who approved publication: Dr Daniel Duprez Holly E Gurgle, Karen White, Carrie McAdam-Marx Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA Abstract: Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control with metformin therapy alone

Low density lipoprotein oxidation is inhibited by extracts of Ilex paraguariensis